Breaks Categories: Stock Spotlights

WednesdayJun 23, 2021 2:14 pm

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Setting Stage for Strengthened Demand for Blue Light Cystoscopy

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is working closely with manufacturing partner Lighthouse Imaging on its proprietary i/Blue Imaging System(TM) and is on target to conduct private demonstrations at the annual American Urology Association meeting set for early September. “The updated product design will incorporate changes intended to meet critical verification requirements established through benchmark testing of competitive systems and feedback from preliminary meetings with the FDA,” reads a recent article. “The additional testing and specification development focused on the contrast agent-induced fluorescence and the ability to replicate the clinical observations in bench-level settings. The sensitivity of the system can…

Continue Reading

TuesdayJun 22, 2021 1:39 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Committed to Driving Novel Treatments Forward with Key Focus on Berubicin

CNS Pharmaceuticals’ (NASDAQ: CNSP) lead drug candidate, Berubicin, is a novel anthracycline, the first of which to appear capable of crossing the blood-brain barrier based on limited clinical data. The company is currently developing Berubicin in the treatment of several serious brain and central nervous system oncological indications. CNS is set to commence patient enrollment in a potentially pivotal study to evaluate the efficacy of Berubicin for adult glioblastoma multiforme (“GBM”) in the second quarter. Additionally, its sublicensee partner in Poland, WPD Pharmaceuticals, will initiate a Phase 2 multicenter clinical trial of Berubicin in adult GBM patients and is also…

Continue Reading

TuesdayJun 22, 2021 1:19 pm

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Advancing Rotigotine Development Program for Parkinson’s

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently announced its drug formulation and development, conducted primarily by its wholly owned German subsidiary, Vektor Pharma TF GmbH, are on schedule and continue to expand in scope. A recent article reads, “A Q1 trial announced in January 2021 and focusing on a human bioavailability pilot study of the Rotigotine transdermal patch for Parkinson’s Disease was completed in March 2021. Due to the favorable outcome of the study, the Rotigotine development program will be advanced to include a pivotal human trial.” The article, which documented XPhyto’s advancements so…

Continue Reading

MondayJun 21, 2021 1:43 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Partnering to Improve Standard of Care, Provide Turnkey Solutions in Plant-Based Medicine

RYAH Group (CSE: RYAH), a connected device and big data and technology company, is working with doctors as well as government and university research centers to reduce the variations in treatment plans and trials. The company, which has developed and uses dose-measuring internet-of-things (“IoT”) devices to collect HIPPA-compliant data to improve future medical treatments, is guided by the need to transform patient care. Key to this focus is utilizing big data and AI to reshape how the world understands plant-based medicine. A recent article reads, “RYAH partners with doctors to improve the standard of care for patients and researchers to…

Continue Reading

MondayJun 21, 2021 11:27 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Revolutionizing Portable EEG Diagnostics Space

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company, has created powerful yet affordable solutions that bring brain diagnostics to settings where it was previously impossible or difficult to conduct neurological testing. Concussions resulting from head trauma in contact sports are usually minor; however, some can lead to significant long-term cognitive, physical and psychosocial impairments. “Unfortunately,” observes a recent article, “at this moment, it is challenging to differentiate between the two.” CT is the most commonly used imaging procedure but is not effective when conducting a post-concussion examination. MRIs and neuropsychologic testing are somewhat more effective but are…

Continue Reading

FridayJun 18, 2021 1:31 pm

BioMedNewsBreaks – United Medical Equipment Business Solutions Network Inc. Differentiating Itself as Premier Provider of Vital Products

United Medical Equipment (“UME,” “UMEBSNI”) stands out in an environment fraught with fraudsters who emerged due to the soaring demand for personal protective equipment (“PPE”). “As the virus spread, an immediate and drastic need for personal protective equipment exploded. This soaring demand for PPE was quickly accompanied by PPE-related fraud,” notes a recent article. PPE fraud involves selling counterfeit testing kits, surgical gowns, gloves, facial masks, and cleaning products, as well as making false or misleading efficacy claims. “As a trusted supplier of FDA-approved COVID-19 rapid antibody test kits and PPE equipment, UME stands out in this environment where buyers…

Continue Reading

ThursdayJun 17, 2021 2:47 pm

BioMedNewsBreaks – Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) Innovative System Expected to Lead to More Successful Surgical Outcomes

Imagin Medical (CSE: IME) (OTCQB: IMEXF) has developed and patented its i/Blue Imaging System(TM), which will directly address the problems associated with treating early stage bladder cancer using existing cystoscope technology. “Current technology shows only one image at a time, requiring the surgeon to constantly switch back and forth between the white and blue light images. The switching process makes orientation and navigation within the bladder a challenge for surgeons,” explains a recent article. Imagin’s system will display real-time white and blue light images simultaneously, side-by-side, removing the challenge of constantly switching and reorienting. In addition, unlike current BLC technology,…

Continue Reading

TuesdayJun 15, 2021 1:59 pm

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Collaborating to Create Safer, More Effective Protocol in ‘Fast-Moving Arena of Psychedelic Therapies’

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is collaborating with psychedelic therapy educational platform Fluence to provide design and training for the psychotherapeutic portion of its Phase 2a clinical trials for treating eating disorders and fibromyalgia. “Fluence is led by researchers and psychotherapists with direct experience in conducting psychedelic clinical trials and is the foremost provider of psychotherapeutic training for health professionals that are administering psychedelic compounds to patients,” reads a recent article. The piece quotes Tryp President and Chief Science Officer Jim Gilligan as saying, “In the fast-moving arena of psychedelic therapies, Fluence has established themselves as the leader in…

Continue Reading

FridayJun 11, 2021 11:21 am

BioMedNewsBreaks – Brain Scientific Inc.’s (BRSF) Disposable Technology Vital Amid Ongoing Pandemic

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, has developed sanitary, disposable EEG caps that are proving useful amid the ongoing pandemic. “When fighting a highly contagious disease, disposable technology is vital,” notes a recent article. This is where NeuroCap(TM) and NeuroEEG(TM), the company’s two FDA-cleared devices, can help. They offer cost-efficient, portable neurological monitoring.” The article observes that EEGs may offer a much-needed solution given that neurological conditions associated with COVID-19 are challenging to diagnose. “For example, the diagnosis of encephalopathy, one of the most frequently occurring neurological conditions in COVID-19, is mainly…

Continue Reading

ThursdayJun 10, 2021 12:42 pm

BioMedNewsBreaks – Healthy Extracts Inc.’s (HYEX) HERHEART(TM) Packs a ‘Whole Host of Health Benefits’

Healthy Extracts (OTCQB: HYEX), through its wholly owned subsidiary BergaMet NA(TM), has developed HERHEART(TM), an exclusive supplement scientifically formulated specifically for women to improve perimenopausal symptoms and cardiovascular health. The supplement’s development was influenced by the statistic that cardiovascular disease is the leading cause of death in women globally. A recent article notes, “A 2020 clinical study revealed that HERHEART reduced mood swings and hot flashes by 40% and 60%, respectively, increased energy by 45%, and improved arousal, comfort and desire by between 40% and 70%. It also reduced cholesterol levels, acted as an anti-inflammatory agent and metabolized fat. Dr.…

Continue Reading